BUZZ-Cytokinetics falls on standard review for heart disease drug

** Shares of Cytokinetics fall 2.3% to $50.67 premarket

** CYTK says U.S. Food and Drug Administration has accepted to review its marketing application for heart disease drug aficamten

** FDA has assigned an action date of Sept. 26, 2025 - CYTK

** At least two analysts said CYTK shares could be weak today due to the standard review period for aficamten vs investor expectations of a priority review that could have led to an earlier launch

** Company is seeking approval of the drug to treat obstructive hypertrophic cardiomyopathy, in which heart muscles become stiff and can cause cardiac arrest

** Truist analysts say that standard review gives CYTK opportunity to submit data for drug as a first-line treatment, which could help set it apart from rival drug, Bristol Myers'

Camzyos

** Piper Sandler says FDA acceptance boosts confidence in the success of the drug, and maintains strong conviction of a less strict label compared to Camzyos

** As of last close, CYTK was down ~48% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))